Hepion Pharmaceuticals Seeks Shareholder Approval to Dramatically Expand Equity Incentive Plan
CTRVP is trading near its 52-week low of $0.001 (0.0% above the low).
Summary
Hepion Pharmaceuticals is proposing a significant expansion of its 2023 Omnibus Equity Incentive Plan, increasing the number of shares available for issuance from 200,000 to 8,000,000.
Key Events · Corporate Governance and Compliance · CTRVP
-
Proposed Equity Plan Expansion
Shareholders will vote on increasing the 2023 Omnibus Equity Incentive Plan from 200,000 to 8,000,000 shares, representing a 3900% increase in the plan's size.
-
Significant Potential Dilution
This authorization could lead to the issuance of up to 7,800,000 additional shares. If valued at the recent $0.04 transaction price, this represents a potential future value of $312,000, a substantial portion of the company's current market capitalization.
-
Annual Meeting Set
The Annual Meeting of Stockholders is scheduled for June 17, 2026, where shareholders will vote on this and other proposals.
Analysis · CTRVP · Life Sciences
Hepion Pharmaceuticals is seeking shareholder approval to dramatically expand its equity incentive plan, increasing authorized shares from 200,000 to 8,000,000. While this represents approximately 1.4% potential dilution relative to current outstanding shares, the potential value of these shares, if issued at the recent $0.04 transaction price from a private placement and insider buys, would be a substantial $312,000. This significant authorization for future compensation, following recent capital infusion and strong insider conviction at a much higher price, indicates the company's intent to incentivize employees at a potentially re-rated valuation. Investors should note the substantial potential dilution while also considering the strategic context of recent financing efforts.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 44.9% of the 1407 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTRVP was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $721.1K. The 52-week trading range was $0.00 to $0.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.